Osteopenia – Epidemiology – Asia Pacific
Clarivate Epidemiology’s coverage of OPE comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of OPE for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe and Japan, and 10 years for the other countries covered in this report.
Clarivate Epidemiology’s OPE forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of OPE over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts five OPE patient populations, as follows:
- Total prevalent cases
- Diagnosed non-drug-treated prevalent cases
- Undiagnosed prevalent cases
- Diagnosed prevalent cases
- Diagnosed drug-treated prevalent cases
Note: coverage may vary by country.
Table of contents
- Osteopenia - Epidemiology - Asia Pacific
- Introduction
- Total Prevalence Estimates of Osteopenia per 1,000 People Aged 40+ in 2021 and 2031
- Total Prevalence Estimates of Osteopenia per 1,000 People Aged 40+ in 2021 and 2031
- Relative Sizes of the Contributing Factors to the Trend in Prevalent Cases of Osteopenia over the Next Ten Years
- Relative Sizes of the Contributing Factors to the Trend in Prevalent Cases of Osteopenia over the Next Ten Years
- Epidemiology Data
- Methods
- Reference Materials
- Introduction
